Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply.
Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: brekke j. J Thromb Haemost. 2022 Aug;20(8):1937-1939. doi: 10.1111/jth.15774. J Thromb Haemost. 2022. PMID: 35859282 Free article. No abstract available.
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Osvik Velle E, Skuterud Wik H, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: brekke j. J Thromb Haemost. 2022 May;20(5):1166-1181. doi: 10.1111/jth.15666. Epub 2022 Feb 20. J Thromb Haemost. 2022. PMID: 35114046 Free article. Clinical Trial.
Arterial events in cancer patients treated with apixaban for venous thrombosis.
Larsen TL, Svalastoga M, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: brekke j. Thromb Res. 2023 Aug;228:128-133. doi: 10.1016/j.thromres.2023.05.017. Epub 2023 May 25. Thromb Res. 2023. PMID: 37327527
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M. Rahman MA, et al. Among authors: brekke j. Immun Inflamm Dis. 2020 Sep;8(3):342-359. doi: 10.1002/iid3.315. Epub 2020 Jun 24. Immun Inflamm Dis. 2020. PMID: 32578964 Free PMC article. Clinical Trial.
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M. Rahman MA, et al. Among authors: brekke j. Br J Cancer. 2019 Oct;121(7):545-555. doi: 10.1038/s41416-019-0551-1. Epub 2019 Aug 15. Br J Cancer. 2019. PMID: 31413318 Free PMC article.
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden.
Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström P, Agrup M, Dahl L, Gubanski M, Gojon H, Brahme CJ, Rydén I, Jakola AS, Vik-Mo EO, Lie HC, Asphaug L, Hervani M, Kristensen I, Rueegg CS, Olsen IC, Ledal RJ, Degsell E, Werlenius K, Blomstrand M, Brandal P. Heggebø LC, et al. Among authors: brekke j. BMJ Open. 2023 Mar 20;13(3):e070071. doi: 10.1136/bmjopen-2022-070071. BMJ Open. 2023. PMID: 36940951 Free PMC article.
Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey.
Gebrehiwet P, Brekke J, Rudnicki SA, Mellor J, Wright J, Earl L, Ball N, Iqbal H, Thomas O, Castellano G. Gebrehiwet P, et al. Among authors: brekke j. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):345-357. doi: 10.1080/21678421.2023.2297795. Epub 2023 Dec 29. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38156828
131 results